vs
Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $4.8M, roughly 1.9× MAXCYTE, INC.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -200.5%, a 201.1% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -20.9%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-2.9M). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -7.4%).
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
MXCT vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $9.3M |
| Net Profit | $-9.6M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | -234.5% | 5.3% |
| Net Margin | -200.5% | 0.6% |
| Revenue YoY | -20.9% | -3.0% |
| Net Profit YoY | 9.4% | 101.3% |
| EPS (diluted) | — | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.8M | $9.3M | ||
| Q3 25 | $4.6M | $6.9M | ||
| Q2 25 | $5.8M | $7.7M | ||
| Q1 25 | $5.7M | $6.8M | ||
| Q4 24 | $6.1M | $9.6M | ||
| Q3 24 | $5.6M | $8.8M | ||
| Q2 24 | $5.0M | $8.4M | ||
| Q1 24 | $5.6M | $6.8M |
| Q4 25 | $-9.6M | $58.0K | ||
| Q3 25 | $-12.4M | $-1.6M | ||
| Q2 25 | $-12.4M | $-2.6M | ||
| Q1 25 | $-10.3M | $-2.1M | ||
| Q4 24 | $-10.6M | $-4.6M | ||
| Q3 24 | $-11.6M | $-2.1M | ||
| Q2 24 | $-9.4M | $-91.0K | ||
| Q1 24 | $-9.5M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | -234.5% | 5.3% | ||
| Q3 25 | -307.4% | -16.9% | ||
| Q2 25 | -244.3% | -30.1% | ||
| Q1 25 | -214.1% | -25.0% | ||
| Q4 24 | -213.1% | -44.7% | ||
| Q3 24 | -250.4% | -18.2% | ||
| Q2 24 | -241.0% | -5.7% | ||
| Q1 24 | -219.8% | -42.7% |
| Q4 25 | -200.5% | 0.6% | ||
| Q3 25 | -269.7% | -23.4% | ||
| Q2 25 | -212.2% | -33.6% | ||
| Q1 25 | -178.7% | -31.2% | ||
| Q4 24 | -175.0% | -47.6% | ||
| Q3 24 | -205.9% | -23.6% | ||
| Q2 24 | -188.8% | -1.1% | ||
| Q1 24 | -170.6% | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | $-0.12 | $-0.36 | ||
| Q2 25 | $-0.12 | $-0.62 | ||
| Q1 25 | — | $-0.51 | ||
| Q4 24 | — | $-2.01 | ||
| Q3 24 | $-0.11 | $-0.51 | ||
| Q2 24 | $-0.09 | $-0.03 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $171.5M | $2.9M |
| Total Assets | $202.5M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.0M | $7.9M | ||
| Q3 25 | $105.7M | $7.1M | ||
| Q2 25 | $126.6M | $6.0M | ||
| Q1 25 | $138.3M | $6.5M | ||
| Q4 24 | $154.5M | $7.3M | ||
| Q3 24 | $153.8M | $7.1M | ||
| Q2 24 | $157.3M | $5.5M | ||
| Q1 24 | $157.5M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $171.5M | $2.9M | ||
| Q3 25 | $180.3M | $1.3M | ||
| Q2 25 | $190.7M | $532.0K | ||
| Q1 25 | $199.4M | $3.0M | ||
| Q4 24 | $206.3M | $5.0M | ||
| Q3 24 | $213.3M | $9.4M | ||
| Q2 24 | $221.3M | $9.5M | ||
| Q1 24 | $226.4M | $9.4M |
| Q4 25 | $202.5M | $30.5M | ||
| Q3 25 | $213.5M | $30.7M | ||
| Q2 25 | $219.8M | $29.5M | ||
| Q1 25 | $230.0M | $33.0M | ||
| Q4 24 | $239.5M | $34.9M | ||
| Q3 24 | $248.6M | $39.4M | ||
| Q2 24 | $251.5M | $38.8M | ||
| Q1 24 | $257.9M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.7M | $-239.0K |
| Free Cash FlowOCF − Capex | $-2.9M | $-551.0K |
| FCF MarginFCF / Revenue | -61.0% | -5.9% |
| Capex IntensityCapex / Revenue | 4.8% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-36.2M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.7M | $-239.0K | ||
| Q3 25 | $-7.5M | $-64.0K | ||
| Q2 25 | $-9.9M | $-1.9M | ||
| Q1 25 | $-14.4M | $-550.0K | ||
| Q4 24 | $-7.8M | $703.0K | ||
| Q3 24 | $-4.4M | $-302.0K | ||
| Q2 24 | $-4.8M | $591.0K | ||
| Q1 24 | $-10.6M | $-804.0K |
| Q4 25 | $-2.9M | $-551.0K | ||
| Q3 25 | $-7.8M | $-1.1M | ||
| Q2 25 | $-10.4M | $-2.0M | ||
| Q1 25 | $-15.1M | $-749.0K | ||
| Q4 24 | $-8.0M | $199.0K | ||
| Q3 24 | $-4.8M | $-364.0K | ||
| Q2 24 | $-5.1M | $246.0K | ||
| Q1 24 | $-11.4M | $-1.5M |
| Q4 25 | -61.0% | -5.9% | ||
| Q3 25 | -168.5% | -15.6% | ||
| Q2 25 | -179.2% | -26.1% | ||
| Q1 25 | -262.3% | -11.0% | ||
| Q4 24 | -131.6% | 2.1% | ||
| Q3 24 | -85.5% | -4.1% | ||
| Q2 24 | -103.3% | 2.9% | ||
| Q1 24 | -203.6% | -22.6% |
| Q4 25 | 4.8% | 3.4% | ||
| Q3 25 | 6.5% | 14.7% | ||
| Q2 25 | 10.0% | 0.8% | ||
| Q1 25 | 11.4% | 2.9% | ||
| Q4 24 | 2.4% | 5.3% | ||
| Q3 24 | 7.2% | 0.7% | ||
| Q2 24 | 5.9% | 4.1% | ||
| Q1 24 | 14.4% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
